A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2996 participants.
Also called NCT01137474
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,996 participants
- Sponsor
- Registry
-
NCT01137474 -
2010-019797-32
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Colombia, Czechia, Denmark, Finland, Germany, Hungary, India, Mexico, Peru, Poland, Puerto Rico, Romania, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01137474. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo-matching dapagliflozin
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01137474- Content hash
fb7208ab172406b937f8fbe3da38caf174fdf812704719c11afd0c392d729f39